ReGen Therapeutics

Regen Therapeutics is a biotechnology company and a subsidiary of Regen BioPharma, Inc., focused on the development of novel therapies targeting the NR2F6 nuclear receptor. NR2F6 is an orphan nuclear receptor that functions as an immune checkpoint; the company is developing small molecule inhibitors to enhance the immune response against cancers such as colon and breast cancer. Additionally, Regen Therapeutics is exploring NR2F6 activators for the treatment of autoimmune diseases like rheumatoid arthritis and psoriasis. The company's pipeline also includes siRNA-based approaches to silence NR2F6 expression in tumor cells. Based in San Diego, the company leverages its proprietary screening platform to identify and optimize compounds for these high-impact therapeutic areas.